BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17285290)

  • 1. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
    Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
    Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
    Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
    Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model.
    Hillman GG; Younes E; Visscher D; Ali E; Lam JS; Montecillo E; Pontes JE; Haas GP; Puri RK
    Cell Immunol; 1995 Feb; 160(2):257-63. PubMed ID: 7720087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
    Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
    Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
    Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
    J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The opposite effect of tumor-infiltrating natural killer cells on in vivo priming of tumor-specific CD8+ T cells and CD4+ T cells.
    Terao H; Harada M; Kurosawa S; Shinomiya Y; Ito O; Tamada K; Takenoyama M; Nomoto K
    Immunobiology; 1996 Jul; 195(2):172-86. PubMed ID: 8877394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of 6-gingerol greatly enhances the number of tumor-infiltrating lymphocytes in murine tumors.
    Ju SA; Park SM; Lee YS; Bae JH; Yu R; An WG; Suh JH; Kim BS
    Int J Cancer; 2012 Jun; 130(11):2618-28. PubMed ID: 21792901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
    Seo N; Hayakawa S; Takigawa M; Tokura Y
    Immunology; 2001 Aug; 103(4):449-57. PubMed ID: 11529935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.